<DOC>
	<DOC>NCT00940485</DOC>
	<brief_summary>This 2 arm study will assess the efficacy and safety of Pegasys in combination or sequential treatment with entecavir in patients with HBeAg positive chronic hepatitis B. Patients who have been pretreated with, and responded to, entecavir for 9 to 36 months were randomized to one of 2 groups, to receive Pegasys 180micrograms/week sc for 48 weeks + entecavir 0.5mg po daily for 8 weeks, or entecavir 0.5mg po daily for 48 weeks. The anticipated time on study treatment is 3-12 months.</brief_summary>
	<brief_title>A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Adult patients, &gt;=18 and &lt;/= 65 years of age HBeAg positive chronic hepatitis B Pretreatment with entecavir for 936 months Antiviral, antineoplastic or immunomodulatory treatment Coinfection with active hepatitis A, C or D, or HIV Evidence of decompensated liver disease History or other evidence of a medical condition associated with chronic liver disease other than viral hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>